FY2025 EPS Estimates for Surmodics Raised by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research increased their FY2025 earnings per share estimates for Surmodics in a research note issued on Thursday, February 27th. Zacks Research analyst D. Dey now expects that the company will post earnings of $0.19 per share for the year, up from their prior estimate of $0.18. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q3 2026 earnings at $0.16 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.20 EPS and FY2027 earnings at $0.84 EPS.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

A number of other research analysts also recently commented on SRDX. StockNews.com assumed coverage on Surmodics in a research note on Monday, February 3rd. They issued a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, Surmodics currently has an average rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Performance

Shares of NASDAQ SRDX opened at $30.49 on Monday. The business’s 50-day moving average price is $36.13 and its two-hundred day moving average price is $38.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. Surmodics has a one year low of $25.17 and a one year high of $42.44. The company has a market capitalization of $435.89 million, a P/E ratio of -30.19 and a beta of 1.20.

Institutional Trading of Surmodics

Large investors have recently made changes to their positions in the stock. Modus Advisors LLC bought a new stake in shares of Surmodics during the 4th quarter worth about $40,000. Quest Partners LLC boosted its stake in shares of Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after acquiring an additional 1,071 shares in the last quarter. R Squared Ltd bought a new stake in shares of Surmodics during the 4th quarter worth about $55,000. Longfellow Investment Management Co. LLC bought a new stake in shares of Surmodics during the 3rd quarter worth about $67,000. Finally, Legal & General Group Plc boosted its stake in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after acquiring an additional 880 shares in the last quarter. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).